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Abstract
Purpose Nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXibs) inhibit the progression 
of endometrial cancer, ovarian cancer and cervical cancer. However, concerning the adverse effects of NSAIDs and COXibs, 
it is still urgent and necessary to explore novel and specific anti-inflammation targets for potential chemoprevention. The 
signaling of cyclooxygenase 2-prostaglandin  E2-prostaglandin  E2 receptors (COX-2-PGE2-EPs) is the central inflammatory 
pathway involved in the gynecological carcinogenesis.
Methods Literature searches were performed to the function of COX-2-PGE2-EPs in gynecological malignancies.
Results This review provides an overview of the current knowledge of COX-2-PGE2-EPs signaling in endometrial cancer, 
ovarian cancer and cervical cancer. Many studies demonstrated the upregulated expression of the whole signaling pathway 
in gynecological malignancies and some focused on the function of COX-2 and cAMP-linked EP2/EP4 and EP3 signaling 
pathway in gynecological cancer. By contrast, roles of EP1 and the exact pathological mechanisms have not been completely 
clarified. The studies concerning EP receptors in gynecological cancers highlight the potential advantage of combining COX 
enzyme inhibitors with EP receptor antagonists as therapeutic agents in gynecological cancers.
Conclusion EPs represent promising anti-inflammation biomarkers for gynecological cancer and may be novel treatment 
targets in the near future.
Keywords Cyclooxygenase-2 (COX-2) · Prostaglandin  E2 receptors (EPs) · Endometrial cancer · Ovarian cancer · Cervical 
cancer
Introduction
Abundant literature has demonstrated a strong correlation 
between chronic inflammation and cancer development since 
chronic inflammation contributes to the development of over 
15% of malignancies worldwide [1]. Plenty of pro-inflamma-
tory factors mediate a role in carcinogenesis, such as tumour 
necrosis factor (TNF), interleukin (IL)-1α, IL-1β, IL-6, 
IL-8, IL-18, matrix metallopeptidase-9 (MMP-9), vascular 
endothelial growth factor (VEGF), cyclooxygenase 2 (COX-
2), and arachidonate 5-lipoxygenase (5-LOX) [2]. Serum 
levels of C-reactive protein (CRP), IL-6, and IL-1 receptor 
antagonist (IL-1Ra) are significantly associated with endo-
metrial cancer risk when analyzing 246,000 women in ten 
European countries [3]. The signaling of cyclooxygenase 
2-prostaglandin  E2-prostaglandin  E2 receptors (COX-2-
PGE2-EPs) is the central inflammatory pathway involved in 
the carcinogenesis (Fig. 1). Based on the current informa-
tion, we aimed to supplement some additional knowledge 
of COX-2-PGE2-EPs in the carcinogenesis of gynecological 
cancer from the perspective of inflammation.
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Biogenesis and signaling: COX‑2‑PGE2‑EPs
Arachidonic acid is released from the membrane phospho-
lipids by phospholipase A2 (PLA2) and then metabolized 
by the enzyme of COX-1 and COX-2 into prostaglandin 
 H2  (PGH2).  PGH2 is converted by specific isomerases 
(PGDS, PGES, PGFS and PGIS) and TXA synthase to var-
ious prostaglandins  (PGE2,  PGD2,  PGF2α,  PGI2) and the 
thromboxane  A2  (TxA2) [4] (Fig. 1). All these prostaglan-
dins  (PGE2,  PGD2,  PGF2α,  PGI2 and  TXA2) act through 
relative specific G-protein coupled receptors (GPCR) to 
mediate their effects, referred to as the EP, DP, FP, IP and 
TP receptors [5] (Fig. 1).
COX enzymes are the primary enzymes in the syn-
thesis of eicosanoids and exist in two isoforms: COX-1 
is considered to be ubiquitously expressed [7], whereas 
COX-2 is expressed predominantly in inflammatory cells 
and upregulated in chronic and acute inflammations [8]. 
COX-1 and COX-2 are located on human chromosomes 9 
and 1 respectively [9]. PGs produced by COX-1 are crucial 
for maintaining the integrity of gastric mucosa, normal 
platelet aggregation and renal function, while PGs derived 
by COX-2 contributes to cancer progression and metas-
tasis [10]. The COX-2 expression is stimulated by differ-
ent growth factors, cytokines and prostaglandins, which 
is associated with inflammatory response and is seen as a 
prognostic factor for malignancy [11, 12]. Furthermore, 
upregulation of COX-2 and  PGE2 has been identified in 
many human cancers and precancerous lesions, and COX 
inhibitory drugs show protective effects in colorectal can-
cer and breast cancer [13].
The three distinct synthases contributing to  PGE2 syn-
thesis are consist of microsomal PGE synthase-1 (mPGES-
1), mPGES-2 and cytosolic PGE synthase (cPGES) [14, 
15]. There are two separate  PGE2-biosynthetic routes: the 
cPLA2-COX-1-cPGES and cPLA2-COX-2-mPGES path-
ways [15]. COX-2 linked to mPGES is essential for delayed 
 PGE2 biosynthesis, which may be linked to inflammation, 
fever, osteogenesis, and cancer [15]. mPGES-1 is primarily 
responsible for increasing  PGE2 levels during inflammation 
and carcinogenesis, and elevated levels of mPGES-1 present 
in a number of human cancers, such as colon, lung, stom-
ach, pancreas, cervix, prostate and head and neck squamous 
carcinoma [16].
PGE2 is the most abundant prostaglandin in humans and 
is known as a key mediator in inflammation. The functions 
of  PGE2 are mainly facilitated by specific membrane-bound 
G-protein-coupled EP receptors (EP1-EP4) with various 
signaling pathways. EP1 is coupled to the G protein alpha q 
 (Gq) to mobilize intracellular  Ca2+, EP2 and EP4 are coupled 
to the G protein alpha stimulator  (Gs) to activate adenylyl 
cyclase (AC), and EP3 is mainly coupled to the G protein 
alpha inhibitor  (Gi) to suppress AC [17]. The EP3 recep-
tor can also be coupled to  G12/13 proteins, resulting in the 
activation of the small G protein Rho [18]. After binding 
its receptor,  PGE2 can be catalyzed by 15-hydroxyprosta-
glandin dehydrogenase (15-PGDH) into an inactive 15-keto 
 PGE2 [6].
In cancer development, EP1 mediates tumor cell migra-
tion, invasion and adjustment to hypoxia environment; 
EP2 induces angiogenesis and suppresses the anti-tumor 
immune response; EP4 can mediate tumor cell migration, 
metastasis, as well as promote aberrant DNA methylation 
[18]. The role of EP3 in carcinogenesis is still unclear with 
conflicting effects in distinct cancer cells. EP3 is a unique 
 PGE2 receptor, since the human EP3 gene consists of ten 
exons and nine introns, encoding at least eight distinct EP3 
splice variants [19]. EP3 isoforms differ in the amino acid 
sequences in their specific C-terminal tails and signal trans-
duction pathways by activating different second messengers 
[20, 21]. This might increase the complexity of investigating 
Fig. 1  COX-2-PGE2-EPs signaling pathway. Arachidonic acid is 
released from the membrane phospholipids by PLA2 and then is 
metabolized by COX-1 and COX-2 into  PGH2.  PGH2 is converted 
by specific isomerases (PGDS, PGES, PGFS and PGIS) and TXA 
synthase to multiple prostaglandins  (PGE2,  PGD2,  PGF2α,  PGI2) 
and the thromboxane  A2 [4]. Prostaglandins act through relative 
receptors (EP, DP, FP, IP and TP) to mediate their effects [5]. The 
inhibitors of COX-2-PGE2-EPs signaling pathway include nonsteroi-
dal anti-inflammatory drugs (NSAIDs), COX-2 selective inhibitors 
(COXIBs), PGES inhibitor, 15-hydroxyprostaglandin dehydrogenase 
(15-PGDH) and EP inhibitors. NSAIDs inhibit the function of both 
COX-1 and COX-2 while COXIBs only inhibit the function of COX-
2.  PGE2 is degraded by 15-PGDH into an inactive 15-keto  PGE2 after 
binding to EP receptors [6]. Both PGES inhibitors and EP inhibi-
tors are novel inhibitors that have been investigating in these years. 
PLA2 phospholipases A2, COX-1 cyclooxygenase-1 COX-2 cycloox-
ygenase-2, PGDS prostaglandin D synthase, PGES prostaglandin G 
synthase, PGFS prostaglandin F synthase, PGIS prostaglandin I syn-
thase, PG prostaglandin, EP prostaglandin E receptor, DP1.2 prosta-
glandin D receptor 1.2, FP prostaglandin F receptor, IP prostaglan-
din I receptor, ATP adenosine triphosphate, cAMP cyclic adenosine 
monophosphate
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the effects of EP3 on the pathological mechanism of can-
cer development. Studies concerning the COX-2-PGE2-EPs 
expression have been investigated recently and are summa-
rized in this review.
Crosstalks with other signaling pathways 
in cancer
Wang et al. elucidated crosstalks interacting with COX-2-
PGE2-EPs signaling pathways in carcinogenesis, mainly 
consisting of the epidermal growth factor receptor (EGFR) 
pathway, nuclear receptor pathway, and Ras-mitogen-acti-
vated protein kinase cascade (Ras-MAPK) pathway [7]. 
The classic and most studied signaling pathway is EGFR 
pathway since both COX-2 and  PGE2 are involved in the 
proliferation, migration and invasion of human colon car-
cinoma cells through EGFR [22, 23]. Combining EGFR 
tyrosine kinase inhibitor (erlotinib) with COX-2 inhibitor 
(celecoxib) can inhibit the tumor cells proliferation of head 
and neck cancer cell lines and the tumor growth of nude 
mouse xenograft models compared with either single agent 
[24]. Moveover, the biomarker expression (antigen Ki67, 
phosphorylated S6 and CD34) of head and neck cancer 
is decreased in 11 cancer patients received the combined 
treatment with erlotinib and celecoxib [24].  PGE2 can also 
trans-activate peroxisome proliferator-activated receptor β/δ 
(PPAR β/δ) via phosphatidylinositol 3-kinase/protein kinase 
B (PI3K/Akt) signaling to promote cell survival of intestinal 
adenoma [25]. In the mice model,  PGE2 can stimulate tumor 
growth of intestinal adenoma in Apcmin mice, but not in Apc-
min mice lacking PPAR β/δ [25]. As a nuclear transcription 
factor, PPAR β/δ binds as heterodimers with a retinoid X 
receptor (RXR) for transcription initiation [26], and the 
natural ligands for PPAR β/δ include fatty acid and  PGE2 
[27]. Additionally,  PGE2 activates Ras-MAPK cascade and 
high expression of  PGE2 can induce COX-2 expression in 
intestinal adenomas [28]. Studies concerning the COX-2-
PGE2-EPs signaling pathway are limited in gynecological 
cancers compared with that in gastrointestinal cancer and 
breast cancer [29].
Endometrial cancer
Endometrial cancer (EC) is the most common gynecologi-
cal malignancy in developed countries, including the United 
States, Canada and Western Europe [30]. There estimated to 
be more than 61,000 new cases of EC and over 12,000 deaths 
in the United States according to the 2019 cancer statistics 
[31]. The main risk factor for EC is exposure to endogenous 
and exogenous estrogens, which is linked to obesity, diabe-
tes, early age at menarche, null parity, late menopause and 
use of tamoxifen [32]. EC is classified into two subtypes: 
type I and type II. Type I is the most common subtype, and 
it is low-grade, endometrioid, diploid, hormone-receptor-
positive endometrial cancer with a good prognosis [32]. By 
contrast, type II EC is high-grade, non-endometrioid, ane-
uploidy, hormone-receptor-negative, TP53-mutated with a 
poor prognosis and a higher risk of metastasis [32].
COX‑2 and endometrial cancer
COX-2 is expressed in the cytoplasm of normal proliferative 
glandular epithelium and endometrial cancer cells [33]. The 
mRNA level of COX-2 is elevated in 51 cancerous endo-
metria compared with 16 normal endometria [34]. COX-2 
is proved to be a negative predictor of disease relapse for 
EC patients in the univariate analysis. COX-2 plays a key 
role not only in the maintenance of the endometrium dur-
ing the menstrual cycle but also in EC carcinogenesis [35]. 
COX-2 overexpression increases angiogenesis, migration, 
invasiveness and tumor-induced immmuno-suppression, as 
well as prevents apoptosis [35]. A combined treatment with 
celecoxib (a COX-2 inhibitor) and rapamycin (a mammalian 
target of rapamycin complex 1 inhibitor, a mTORC1 inhibi-
tor) reduces EC progression in mouse models of EC and 
human EC cell lines [36]. Brasky et al. demonstrated that 
treatment of aspirin could reduce the risk of EC, especially 
in estrogen-mediated cases by analyzing 22,268 female 
Americans after up to 10 years [37]. In clinical studies, the 
correlation of COX-2 expression and EC patients’ prognosis 
still remains conflicting [38, 39].  PGE2 is associated with 
both endometrial functions and disorders. Ke et al. found 
that prostaglandin E synthase 2 (PTGES2) is upregulated in 
the 119 endometrial cancer tissues compared with 50 normal 
endometria, and PTGES2 is associated with the endometrial 
carcinoma stage, grade and the depth of myometrial inva-
sion [40].
EPs expression in endometrial cancer
Zhu et al. suggested that six patients with higher EP1 staining 
survived after seven years follow-up, although EP1 expres-
sion was not correlated to progression-free survival or overall 
survival of endometrial cancer patients [41]. More recruited 
EC patients’ samples might further prove the connection of 
EP1 expression and EC (Fig. 2). The biosynthesis of EP2, EP4 
and cAMP are significantly elevated in response to  PGE2 in 
endometrial adenocarcinoma tissues compared with normal 
endometria by quantitative PCR [42].  PGE2 stimulates vascu-
lar endothelial growth factor (VEGF) expression in Ishikawa 
cells (a human endometrial adenocarcinoma cell line) via EP2-
cAMP-mediated transactivation of the epidermal growth factor 
receptor (EGFR) and extracellular signal-regulated kinases 1/2 
(ERK1/2) pathways [43]. Battersby and his colleagues proved 
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that  PGE2 upregulates the expression of fibroblast growth 
factor 2 (FGF2) via the EP2 receptor in a cAMP-, c-Src-, 
epidermal growth factor receptor (EGFR)- and extracellular 
signal-regulated kinase (ERK)-dependent manner in Ishikawa 
cells [44]. FGF2 is a potent mitogenic and angiogenic factor, 
causing adenocarcinoma cell proliferation in nude mice trans-
planted subcutaneously with endometrial adenocarcinoma 
[45].  PGE2 can enhance proliferation and invasion of two 
human endometrial cancer cells (Ishikawa and HEC-1B) by 
stimulating EP4 receptor and small ubiquitin-like modifier-1 
(SUMO-1) via the Wnt/β-catenin signaling pathway [40].
The proliferation and angiogenesis of implanted tumor can 
be directly inhibited in EP3−/− mice, as well as suppressed 
by an EP3 antagonist (ONO-AE3–240) in wild-type mice 
[46]. EP3 mRNA is expressed abundantly in the uterus [47]. 
The latest study by our research group demonstrated that high 
expression of EP3 correlates with poor progression-free sur-
vival and overall survival in endometrial carcinoma [48]. Our 
group also proved that L-798,106 (a specific EP3 antagonist) 
induces the expression of estrogen receptor β and inhibits the 
activity of Ras, leading to decreased proliferation and migra-
tion of RL95-2 cells [48]. Overexpression of estrogen receptor 
β (ERβ) inhibits proliferation and invasion of tumor cells in 
breast cancer and endometrium [49, 50].
Ovarian cancer
Ovarian cancer ranks the fifth as a cause of neoplastic death 
among women worldwide [30] and the first lethal gyneco-
logical malignancy [31]. There would be around 22,530 new 
cases and 13,980 deaths in the United States in 2019 [31]. 
Incidence rates are highest in more developed regions, with 
rates of more than 7.5 per 100,000 [30]. The overall 5-year 
survival rate of ovarian cancer is just approximately 30–40% 
[51]. The fundamental problem in treating ovarian cancer is 
that it is not easy to discover it at an early stage and accom-
plish complete curative resection. Ovarian cancer histologi-
cal groups include type I epithelial, type II epithelial, germ 
cell, sex cord-stromal, other specific non-epithelial and non-
specific tumors [52]. Among all the subtypes, type II epithe-
lial tumors are the most common in Oceania, North America 
and Europe, while type I epithelial tumors are more common 
in Asia during 2005–2009 [52]. Type II epithelial tumors are 
associated with poorer survival than type I epithelial, germ 
cell and sex cord-stromal tumors [52].
COX and ovarian cancer
COX-2−/− female mice show defective ovulation, fertiliza-
tion and implantation [53]. The mRNA expressions of COX-
1, COX-2, EP2 and EP4 are detected in both granulosa and 
cumulus cells in mice periovulatory follicles during supero-
vulation [54]. COX-1, COX-2, mPGES-1, EP1 and EP2 are 
expressed predominantly in epithelial cells of human epi-
thelial ovarian cancer [55]. Kino et al. (2005) believed that 
COX-1 is the primary enzyme for producing  PGE2 instead of 
COX-2 in ovarian cancer cells. Because the elevated expres-
sion of COX-1 instead of COX-2 was detected in 22 ovarian 
cancer tissues compared with that in normal cases [56], and 
SC-560 (a COX-1 inhibitor) can suppress the production 
of  PGE2 in three ovarian cancer cell lines while NS-398 
and rofecoxib (COX-2 inhibitors) can not [56]. However, the 
latest meta-analysis (2017) suggested that COX-2 expres-
sion is correlated with FIGO stage, histological type and 
patients’ age and the high expression of COX-2 is associated 
with reduced OS and DFS of ovarian cancer patients [57]. 
In addition, high expression of COX-2 is associated with 
a shorter progression time and overall survival time in the 
patients who firstly underwent explorative laparotomy and 
then received chemotherapy [58]. It implies that COX-2 is 
also correlated with chemotherapy resistance.
For in vitro studies, COX-2 can stimulate the prolifera-
tion, migration and angiogenesis of ovarian cancer cells. 
COX-2 enhances proliferation and migration of human 
ovarian cancer CAOV-3 cells mainly through the activation 
of phosphatidylinositol 3-kinase/protein kinase B (PI3-k/
Akt) pathway [59]. By analyzing the epithelial ovarian 
Fig. 2  Overview the expression of COX-2-PGE2-EPs signal-
ing in gynecological malignancies (endometrial cancer, ovar-
ian cancer and cervical cancer). Red arrow: upregulation; green 
arrow:downregulation; -: uncertain
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cancer (EOC) tissues and EOC cell lines (MDAH2274 
and SKOV3), Uddin and his colleagues demonstrated that 
COX-2 modulates cell growth and apoptosis also through 
PI3K/AKT signaling pathway in EOC [60]. Furthermore, 
Uddin et al. proved that COX-2 could be a potential ther-
apeutic target in EOC because treatment of xenografts 
together with aspirin can inhibit tumor growth in nude mice 
through decreasing the expression of COX-2 and Akt [60]. 
COX-2 protein levels correlate with VEGF protein levels and 
microvessel counts in ovarian carcinoma [61].
The expression of COX-2 is regulated by various 
cytokines in ovarian cancer cells, such EGF, vitamin D, 
IL-1β. EGF induces the production of both COX-2 and 
 PGE2 via the activation of the PI3K/Akt signaling pathway, 
resulting in an invasion of SKOV3 and OVCAR5 cells (two 
human ovarian cancer cell lines) [62]. A reduced level of 
vitamin D receptor (VDR) and an induced level of COX-
2, 15-PGDH and  PGE2 are found in the serum of ovarian 
cancer patients older than 45 years [63], suggesting an inter-
action between PG and vitamin D-metabolism in ovarian 
cancer. The mRNA and protein expression of COX-2 can be 
stimulated by IL-1β and phorbol ester (TPA) in OVCAR-3 
cells and by TPA in CAOV-3 cells [64].
EPs and ovarian cancer
PGE2 can induce cell invasiveness via increasing the expres-
sion of MMP-2 and MMP-9 in two human ovarian cancer 
cell lines (CaOV-3 and SKOV-3) [65].  PGE2 stimulates the 
VEGF production in HEY ovarian cancer cells mainly via 
activating EP2 and EP4 receptors, which can be reversed 
by AH23848 (an antagonist of both EP2 and EP4) [66]. In 
addition,  PGE2-induced EP4 receptor signaling induces 
MMP production and ovarian cancer cell invasion through 
Src-mediated EGFR transactivation [66]. EP2 plays a vital 
role in the process of ovulation and fertilization because 
cumulus expansion becomes decreased in EP2−/− mice [67]. 
By feeding hens 10% flaxseed-enriched or standard diet for 
four years, Eilati et al. proved a decreased expression of 
COX-2 and  PGE2, as well as a reduction in ovarian cancer 
severity and incidence [68]. Our research group (2019) has 
recently demonstrated that EP3 expression was higher in 
clear-cell carcinoma compared to three other histological 
subtypes of ovarian cancer [69]. Moreover, EP3 negative 
patients showed longer overall survival in a subgroup with 
negative expression of a tumor-specific epitope of tumor-
associated epithelial mucin 1 (MUC1) [69].
Cervical cancer
Cervical cancer is the fourth most common cancer and the 
fourth most common cause of cancer-related death among 
women worldwide [70]. The incidence and prevalence of 
cervical cancer are higher in the developing countries than in 
the developed countries owing to a lack of screening, avail-
ability of vaccine, and awareness of HPV infections [71]. In 
the United States in 2019, there were an estimated 13,170 
cases and 4250 deaths from cervical cancer [31]. In many 
developing countries, cervical cancer causes more than one-
quarter of a million deaths per year [72]. The 5-year survival 
rate of cervical cancer is between 63–79% in China, Sin-
gapore, South Korea and Turkey, less than 25% in Gambia 
and Uganda [73]. The two main malignant epithelial cervi-
cal cancer types are the squamous cell carcinoma and the 
adenocarcinoma [74].
COX‑2 and cervical cancer
High expressions of COX-2 and  PGE2 have been found in 
the cervical carcinoma [75, 76]. COX-2 is overexpressed in 
various types of cervical neoplasm such as cervical intraepi-
thelial neoplasia (CIN), adenocarcinoma and squamous cell 
carcinoma, implying that COX-2 expression is highly associ-
ated with cervical carcinoma development and progression 
[10]. Many studies show that COX-2 contributes to carcino-
genesis and progression of cervical cancer. High expression 
of COX-2 is related to poor overall survival (OS) and poor 
disease-free survival (DFS) in cervical cancer patients [77]. 
COX-2 is also associated with poor DFS in chemo-radia-
tion subgroup, implying COX-2 is a chemo-radiation resist-
ance predictive factor for cervical cancer [77]. The COX-2 
expression is more frequently expressed in adenocarcinoma 
than in squamous cell carcinoma by immunohistochemistry 
[78]. The co-expression of COX-2 and thymidine phosphor-
ylase (TP) is related to poor 5-year disease-free and overall 
survival rates, suggesting that the combination of COX-2 
and TP is a prognosticator for squamous cell carcinoma of 
the cervical cancer [79].
The expression of mPGES-1 is higher in squamous 
intraepithelial lesions and carcinoma of the uterine cer-
vix compared with the normal cervical epithelium [80]. 
Radilova et  al. found that COX-1 is also coupled with 
mPGES-1 for co-regulating  PGE2 synthesis in human cervix 
cancer cells [81]. Dimethylcelecoxib (a non-COX-2 inhibi-
tor) inhibits the early growth response protein 1 (EGR1) 
and transcription of mGPES-1 via an enhanced complex of 
NF-κB and histone deacetylase 1 (HDAC1) that binds to the 
EGR1 promoter in Hela cells [82].
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EPs and cervical cancer
Sales et al. reported that the syntheses of COX-2,  PGE2, 
EP2, EP4 and cyclic adenosine monophosphate (cAMP) are 
up-regulated in cervical cancer tissue compared to that in 
the healthy cervix, suggesting that  PGE2 may regulate neo-
plastic cell function via the EP2/EP4 receptors [75]. Sales 
and his colleagues further in 2002 proved that  PGE2 could 
induce the expression of COX-2, EP4 and cAMP in Hela 
cells which were transiently transfected with EP2 or EP4 
cDNA [76]. However, this research did not detect whether 
the expression of cAMP would be decreased after knock-
ing out or knocking down the expression of EP2 or EP4. 
Kurt et al. observed that rapid accumulation of cAMP is 
produced in Hela cells after being stimulated with  PGE2, 
which is mediated via the cAMP-linked EP2/EP4 receptors 
[76]. Both studies imply that  PGE2 regulates the function 
of cervical cancer cells mainly via cAMP-linked EP2/EP4 
signaling pathway.
Jung-Min et al. showed an increased expression of EP4 
in 52 cervical cancer tissues compared with four healthy 
controls by immunohistochemistry [83]. This study also 
demonstrated that HPV16 E5 upregulated the activity of 
 PGE2-EP4-cAMP signaling pathways by inducing the bind-
ing of cyclic adenosine monophosphate response element-
binding protein (CREB) to a variant CRE site in the pro-
moter of the human EP4 gene [83]. EP4 plays a role in the 
proliferation and angiogenesis of cervical cancer cells since 
GW627368X (a highly selective EP4 antagonist) inhibits 
the proliferation and angiogenesis of cervical carcinoma by 
blocking EP4/EGFR signaling pathway in cervical cancer 
cell lines (HeLa, SiHa and ME 180) and suppresses the 
tumor size in xenograft mice model [84].
Our group recently proved that overexpression of EP3 in 
cervical cancer patients is associated with impaired prog-
nosis in overall survival rates when evaluating 250 cervi-
cal cancer patients with immunohistochemistry [85]. As 
an independent prognosticator for cervical carcinoma, the 
EP3 receptor is also significantly correlated with lymph 
node stage and FIGO stage [85]. However, the pathologi-
cal mechanism of how EP3 signaling regulates in cervical 
cancer is still unclear.
Drug targeting of COX‑2‑PGE2‑EPs signaling
Chemoprevention has long been recognized as an impor-
tant prophylactic strategy to reduce the burden of cancer 
on the health care system. In addition, nonsteroidal anti-
inflammatory drugs (NSAIDs) as chemoprevention chemi-
cals have been proved to reduce the risk of several cancers 
in human, such as gastrointestinal cancer, breast cancer, 
prostate cancer, lung cancer and skin cancer [86]. Nan et al. 
(2015) found that regular use of aspirin or NSAIDs is linked 
to lower risk of colorectal cancer compared with no regular 
use after analyzing 8634 colorectal cancer cases and 8553 
matched controls between 1976 and 2011 [87]. Long-term 
use of COX inhibitors in humans leads to a 50% decrease in 
risk for colorectal cancer [25]. A meta-analysis by Banndrup 
et al. suggested the risk of invasive ovarian cancer is signifi-
cantly reduced with the use of aspirin [88].
NSAIDs include aspirin, ibuprofen and naproxen, and 
act by inhibiting both COX-1 and COX-2. These unspecific 
inhibitors cause many adverse effects, such as gastrointesti-
nal ulcers and bleeds, heart attack and kidney disease [89]. 
Selective COX-2 inhibitors (COXibs) has been successfully 
documented and showed less toxicity to gastrointestinal tract 
as compared to traditional NSAIDs [90]. However, the long-
term use of COX-2 selective inhibitors still has other side 
effects. The adverse effects of COX-2 selective and non-
selective inhibitors are summarized in the latest review by 
Rayar et al. including myocardial infarction, hypertension, 
stroke, reduced glomerular filtration rate and renal plasma 
flow, acute renal failure, acute interstitial nephritis, inhibi-
tion of ulcer healing, hepatic complications, allergy, fatal 
skin reaction, depression, delayed follicular rupture and so 
on [91]. Therefore, further exploration of novel anti-inflam-
mation targets is needed.
Clinical studies show elevated levels of mPGES-1 are 
identified in colon, lung, stomach, pancreas, cervix, pros-
tate, papillary thyroid carcinoma, head and neck squmaous 
carcinoma and brain tumors, suggesting mPGES-1 inhibitors 
might be a potential chemopreventive agent [16]. However, a 
limited number of compounds that inhibiting mPGES-1 has 
not been successfully developed as anti-cancer agents, such 
as celecoxib, MF-63, NS-398, MK-866 and triclosan [16].
In recent years, extensive efforts have been made into 
elucidating the function of  PGE2 and the EP receptors in 
health and carcinogenesis with the aim of exploring promis-
ing targets and selective inhibitors as a novel therapy. Many 
researchers have found the strong correlation of EP2/EP4 
receptors with colon cancer, skin cancer, mucosa cancer of 
the pharynx and the esophagus, prostate cancer, urothelial 
cancer and non-small cell lung cancer [18]. The EP4 pro-
motes migration, invasion, angiogenesis and lymphangi-
ogenesis of mammary tumor cells [92]. EP4 receptor is 
responsible for the  PGE2-induced colorectal tumor cell 
proliferation and morphogenic changes via PI3k/Akt sign-
aling pathway [93]. Mice are not able to have inflamma-
tory responses to  PGE2, IL-1β or lipopolysaccharide when 
lacking the EP3 receptor, but not EP1, EP2 or EP4 receptor 
[94]. Deletion or inhibition of EP3 receptors could amelio-
rate the neuronal apoptosis in the ischemic cortex in EP3 
knock-out mice or EP3 antagonist-treated mice compared 
with wild-type mice or vehicle-treated mice, respectively. 
It suggests that EP3 is involved in the inflammatory and 
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apoptotic reactions during stroke injury [95]. The investi-
gations concerning EP receptors in gynecological cancers 
highlight the potential advantage of combining COX enzyme 
inhibitors with EP receptor antagonists as therapeutic agents 
in gynecological cancers.
Wang et al. proposed the possible  PGE2 downstream tar-
gets that might also serve as promising specific chemopre-
ventive agents for cancer prevention and treatment, which 
include angiogenic factors (VEGF, bFGF), anti-apoptotic 
factors (Bcal-2), chemokines (MIP-1α, MIP-1β, RANTES, 
CXCR4) and their receptors, and immunosuppressive media-
tors [7].
Conclusions
Studies show that COX-2 is a negative predicator of EC, 
ovarian cancer and cervical cancer, contributing to car-
cinogenesis and progression of gynecological cancer. The 
expression of mPGES-1 is highly expressed in human epi-
thelial ovarian cancer and cervical cancer, while PTGES2 
is associated with the endometrial carcinoma carcinogen-
esis. Many studies focus the function of cAMP-linked 
EP2/EP4 signaling pathway in EC, ovarian cancer and 
cervical cancer, while roles of EP1 and EP3 have not been 
completely clarified. Further investigations concerning EP 
receptors in gynecological cancers are necessary. EPs may 
represent novel and specific anti-inflammation targets for 
gynecological cancer chemoprevention. It might highlight 
the potential advantage of combining COX enzyme inhibi-
tors with EP receptor antagonists as therapeutic agents in 
gynecological cancer.
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